Stephanie Davis
Stock Analyst at Barclays
(0.58)
# 4,098
Out of 5,090 analysts
94
Total ratings
31.82%
Success rate
-109.57%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $190 → $195 | $182.51 | +6.84% | 7 | Oct 22, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $34.35 | +31.00% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $14.24 | -64.89% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $45.93 | +63.29% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.48 | +8.02% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.71 | +121.40% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.94 | +382.23% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $339.66 | -14.62% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $198.83 | -33.11% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $40.50 | +43.23% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.08 | -2.60% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $258.39 | -3.63% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $20.29 | +42.93% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.59 | +347.96% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $24.02 | +41.55% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $242.00 | -3.72% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.60 | +553.85% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $94.51 | -19.59% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 22, 2025
Maintains: Equal-Weight
Price Target: $190 → $195
Current: $182.51
Upside: +6.84%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $34.35
Upside: +31.00%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $14.24
Upside: -64.89%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $45.93
Upside: +63.29%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.48
Upside: +8.02%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.71
Upside: +121.40%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.94
Upside: +382.23%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $339.66
Upside: -14.62%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $198.83
Upside: -33.11%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $40.50
Upside: +43.23%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.08
Upside: -2.60%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $258.39
Upside: -3.63%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $20.29
Upside: +42.93%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.59
Upside: +347.96%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $24.02
Upside: +41.55%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $242.00
Upside: -3.72%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.60
Upside: +553.85%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $94.51
Upside: -19.59%